Cellectis S.A.
NASDAQ:CLLSBiotechnology
-$0.02 today
- Market cap
- $103.75M
- Beta
- 2.75
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.67
Volume 0.01M
Average 0.04M
CLLS Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Cellectis S.A.NASDAQ: CLLS
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow growth accelerates
Q1 FY2026 financing cash flow of $4.83M (cash outflow) rose 18.0% year over year, ahead of the -123.8% change in trailing-twelve-month financing cash flow. Sequentially, it rose 19.8% from the prior quarter.
Context
- Financing cash flow amounted to 22.2% of revenue in FY2025, down 194.2 pp from a year earlier.
- Financing cash flow increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +18.0% holds above the trailing-twelve-month pace of -123.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (16.2M) USD
- Year-over-year change
- -118.0%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (16.2M) | -118.0% |
| FY2024 | 2024-12-31 | 89.8M | +8.4% |
| FY2023 | 2023-12-31 | 82.87M | +7137.1% |
| FY2022 | 2022-12-31 | 1.15M | -97.6% |
| FY2021 | 2021-12-31 | 47.53M | — |
Financing Cash Flow vs competitors
How CLLS compares with its peers on the latest reported figures
- Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -123.8% is the lowest of 9, against a peer median of +77.9%.
- Financing cash flow amounts to 25.5% of revenue for CLLS, versus a peer median of 19.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $365.04M USD | +52499.0% | +12.5% | — | |
| LTM Mar 2026 | $173.2M USD | +64727.2% | -4.7% | — | |
| LTM Mar 2026 | $165.89M USD | +1517.0% | +11.1% | — | |
| LTM Mar 2026 | $88.73M USD | +27.9% | +236.4% | 2309.3% | |
| LTM Dec 2025 | $45.77M USD | — | -22.1% | — | |
| LTM Mar 2026 | $17.39M USD | -123.8% | — | 25.5% | |
| LTM Mar 2026 | $2.59M USD | +127.8% | +75.3% | 1.2% | |
| LTM Dec 2025 | CHF 1.02M CHF | -9.0% | -10.2% | 28.5% | |
| LTM Mar 2026 | $191.89K USD | -76.4% | -2.7% | — | |
| LTM Mar 2026 | $95.27K USD | -100.2% | +17.8% | 19.1% | |
| LTM Mar 2026 | $911.01 USD | — | -93.4% | 0.1% | |
| Peer median (excluding CLLS) | — | +77.9% | +4.2% | 19.1% | |
Competitors are the stored peer set for CLLS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (96.75M) | (98.69M) | (116.84M) | (36.7M) | (67.8M) |
| Depreciation & Amortization | 14.16M | 18.44M | 18.52M | 19.84M | 20.12M |
| Deferred Income Tax | 0 | 87K | 371K | 0 | 0 |
| Stock-Based Compensation | 11.49M | 6.04M | 5.23M | 0 | 0 |
| Change in Working Capital | (12.3M) | (5.72M) | (3.99M) | 53.57M | (41.72M) |
| Accounts Receivables | (12.44M) | (8.99M) | 2.25M | (6.72M) | (4.44M) |
| Inventory | 215K | 0 | 0 | 0 | 0 |
| Accounts Payables | 177K | 3.25M | (6.31M) | 2.05M | (3.27M) |
| Other Working Capital | (252K) | 23K | 67K | 58.24M | (34.01M) |
| Other Non-Cash Items | (21.17M) | (7.6M) | 71.95M | (14.61M) | 49.26M |
| Operating Cash Flow | (104.56M) | (87.44M) | (24.75M) | 22.1M | (40.14M) |
| Capital Expenditures | (18.56M) | (2.44M) | (1.07M) | (2.58M) | (2.37M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (143K) | 0 | 0 | (162.48M) | (160.27M) |
| Sales of Investments | 15M | 126K | 0 | 63.69M | 134.24M |
| Other Investing Activities | 10.97M | (456K) | (14.44M) | 0 | 0 |
| Investing Cash Flow | 7.28M | (2.76M) | (15.51M) | (102.63M) | (29.58M) |
| Debt Repayment | (10.64M) | (6.6M) | 24.56M | 18.17M | (5.4M) |
| Common Stock Issued | 44.64M | 0 | 67.94M | 82.68M | 44.14K |
| Common Stock Repurchased | 0 | (569K) | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 13.53M | 8.32M | (9.64M) | (11.04M) | (10.85M) |
| Financing Cash Flow | 47.53M | 1.15M | 82.87M | 89.8M | (16.2M) |
| Effect of Forex Changes | (5.75M) | (3.36M) | 884K | (2.73M) | 6.24M |
| Net Change in Cash | (55.51M) | (92.42M) | 43.49M | 6.54M | (79.67M) |
| Free Cash Flow | (123.12M) | (89.89M) | (25.82M) | 19.52M | (42.5M) |
Cellectis S.A.
NASDAQ:CLLS
Intrinsic Alpha fair value
Locked
Current Price
$1.03
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.